Compares the effectiveness of GnRH antagonists and dienogest in treating chronic pelvic pain in endometriosis, suggesting tailored approaches for better outcomes.
Dienogest and oral GnRH antagonists share anti-inflammatory and anti-proliferative effects but differ in pharmacodynamics and safety. Dienogest remains a well-tolerated long-term option in estrogen-sensitive patients, whereas GnRH antagonists are better suited for severe or refractory cases requiring rapid control. Integrating molecular and clinical profiling will be crucial to optimize individualized therapy and long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Palumbo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: